This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biomarin Pharmaceutical Inc (BMRN)

NASDAQ: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 889.89M 751.04M 548.49M 500.72M
Cost of Sales 120.33M 83.78M 61.31M 60.78M
Gross Operating Profit 769.56M 667.26M 487.17M 439.94M
Selling, General, and Administrative Expenses 402.27M 302.16M 235.36M 198.17M
Research & Development 634.81M 461.54M 354.78M 302.22M
Operating Income before D & A (EBITDA) -267.52M -96.44M -102.96M -60.45M
Depreciation & Amortization 49.36M 63.95M 53.04M 49.76M
Interest Income 4.50M 5.94M 3.08M 2.58M
Other Income - Net 736.42M 67.11M -11.98M -1.79M
Special Income / Charges -568.20M 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -144.97M -88.23M -166.06M -110.64M
Interest Expense 9.75M 36.64M 10.45M 7.64M
Pre-Tax Income -154.72M -124.87M -176.50M -118.28M
Income Taxes 17.07M 9.10M -150.00K -3.93M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -171.80M -133.97M -176.35M -114.35M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -171.80M -133.97M -176.35M -114.35M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -171.80M -133.97M -176.35M -114.35M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
396.40M -133.97M -176.35M -114.35M
Preferred Dividends
Net Income Available To Common -171.80M -133.97M -176.35M -114.35M
Basic EPS from Continuing Ops. -1.07 -0.92 -1.28 -0.95
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -1.07 -0.92 -1.28 -0.95
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -1.07 -0.92 -1.28 -0.95
Basic Normalized Net Income/Share 2.48 -0.92 -1.28 -0.95
EPS fr Continuing Ops. -1.07 -0.92 -1.28 -0.95
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -1.07 -0.92 -1.28 -0.95
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -1.07 -0.92 -1.28 -0.95
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
2.48 -0.92 -1.28 -0.95
Dividends Paid per Share 0.00 0.00 0.00 0.00
BMRN News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

BMRN Biomarin Pharmaceutical Inc

Chart of BMRN

Analysts Ratings for BMRN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 12 11 10 9
Moderate Buy 2 2 2 1
Hold 2 2 3 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET BMRN ANALYST REPORT

BMRN Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs